Get the Stockscreener App
41.76
0.36%
-0.15
After Hours:
41.98
0.22
+0.53%
Qiagen Nv stock is traded at $41.76, with a volume of 1.43M.
It is down -0.36% in the last 24 hours and up +2.86% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$41.91
Open:
$41.89
24h Volume:
1.43M
Relative Volume:
0.61
Market Cap:
$8.61B
Revenue:
$2.09B
Net Income/Loss:
$424.88M
P/E Ratio:
20.43
EPS:
2.0439
Net Cash Flow:
$447.20M
1W Performance:
+4.06%
1M Performance:
+2.86%
6M Performance:
-12.08%
1Y Performance:
-1.32%
1-Day Range:
$41.74
$42.33
1-Week Range:
$40.33
$42.33
52-Week Range:
$38.80
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
41.76 | 8.43B | 2.09B | 424.88M | 447.20M | 2.0439 |
TMO
Thermo Fisher Scientific Inc
|
527.22 | 184.37B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.61 | 134.19B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
584.05 | 44.72B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
120.39 | 32.52B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
330.98 | 31.41B | 3.17B | 642.63M | 516.49M | 10.77 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-22-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
QIAGEN launches bloodstream infection testing panel - StreetInsider
QIAGEN (QGEN) Launches New Panel for Bloodstream Infections - GuruFocus
Qiagen launches bloodstream infection testing panel By Investing.com - Investing.com Canada
QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel - Business Wire
Barclays Downgrades Qiagen NV(QGEN.US) to Hold Rating, Cuts Target Price to $44 - Moomoo
QIAGEN NV : Barclays is less optimistic - marketscreener.com
Barclays Downgrades QIAGEN to Equalweight From Overweight, Adjusts Price Target to $44 From $48 - marketscreener.com
Qiagen N.V. stock (NL0012169213): Is sample-to-insight leadership strong enough to unlock new upside - AD HOC NEWS
Precision Trading with Qiagen N.v. (QGEN) Risk Zones - Stock Traders Daily
Qiagen N.V. stock (NL0012169213): Why does its molecular diagnostics edge matter more now for U.S. i - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Is its genomics leadership strong enough to unlock new upside? - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Does its genomics leadership deliver the biotech stability U.S. in - AD HOC NEWS
Big Money Moves: Is Qiagen NV backed by strong institutional buying2026 Price Momentum & Detailed Earnings Play Strategies - baoquankhu1.vn
Massachusetts Financial Services Co. MA Increases Stock Position in Qiagen N.V. $QGEN - MarketBeat
Trading Recap: Is Qiagen NV backed by strong institutional buyingTrade Ideas & Stepwise Trade Execution Plans - baoquankhu1.vn
Chipmakers Recap: Is Qiagen NV exposed to political risk2026 Biggest Moves & Fast Moving Stock Trade Plans - baoquankhu1.vn
Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - GlobeNewswire Inc.
Fed Watch: Why is Qiagen NV stock going up2026 Institutional Moves & Expert Curated Trade Setup Alerts - baoquankhu1.vn
QGEN Stock Price, Quote & Chart | QIAGEN N.V. (NYSE:QGEN) - ChartMill
BlackRock Discloses Double-Digit Stake in Qiagen - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView — Track All Markets
Release according to Article 40, Section 1 of the WpHG - TradingView — Track All Markets
QGEN PE Ratio & Valuation, Is QGEN Overvalued - Intellectia AI
How Investors May Respond To Qiagen (QGEN) Upgrade After Reaffirmed 5% Outlook And New Product Plans - Sahm
Aug Levels: How does Qiagen NV score in quality rankingsQuarterly Risk Review & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Qiagen (QGEN) upgraded to buy by Deutsche Bank after 30% decline - MSN
Momentum Shift: Why is Qiagen NV stock going up2026 Pullback Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
QGEN Technical Analysis & Stock Price Forecast - Intellectia AI
Qiagen N.V. (NYSE:QGEN) Given Average Rating of "Hold" by Brokerages - MarketBeat
Qiagen N.V. (QGEN) Rolls Out QIAstat-Dx Rise, Expands U.S. Testing Access - MSN
Qiagen N.V. (QIA.DE) stock price, news, quote and history - Yahoo Finance UK
Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider - GlobeNewswire Inc.
Bank of America Discloses 3.01% Voting Stake in Qiagen - TipRanks
Qiagen (QGEN) Upgraded to Buy by Deutsche Bank After 30% Decline - Insider Monkey
Bruker appoints QIAGEN CEO Thierry Bernard to board of directors By Investing.com - Investing.com South Africa
Qiagen N.V. Stock: Leader in Molecular Diagnostics Faces CEO Transition Amid Steady Growth Outlook - AD HOC NEWS
Bruker appoints QIAGEN CEO Thierry Bernard to board of directors - Investing.com
Bruker brings in QIAGEN chief Thierry Bernard for board seat - Stock Titan
List of 26 Acquisitions by Qiagen (Apr 2026) - Tracxn
Bear Alert: Whats next for Qiagen NV stock2026 Weekly Recap & Risk Managed Investment Strategies - baoquankhu1.vn
Qiagen N.V. Stock: Oversold Opportunity in Sample-to-Insight Leader Amid Biotech Sector Shifts - AD HOC NEWS
Allspring Global Investments Holdings LLC Boosts Position in Qiagen N.V. $QGEN - MarketBeat
QIAGEN NV Hits New 52-Week Low at USD 38.80 Amid Declining Performance - Markets Mojo
AlphaValue/Baader Europe Upgrades Qiagen to Buy - marketscreener.com
The Bull Case For Qiagen (QGEN) Could Change Following New QuantiFERON-TB Gold Plus EvidenceLearn Why - simplywall.st
Qiagen (QGEN) Valuation Check As New QuantiFERON TB Data Reinforces Leadership In Tuberculosis Detection - Sahm
Qiagen NV at Leerink Global Healthcare Conference Transcript - GuruFocus
Qiagen (NYSE:QGEN) Cut to "Hold" at Wall Street Zen - MarketBeat
Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities - AD HOC NEWS
Qiagen (NYSE:QGEN) Sets New 52-Week LowTime to Sell? - MarketBeat
Aug Highlights: Should I set a stop loss on Qiagen NVProfit Target & High Conviction Investment Ideas - baoquankhu1.vn
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):